Product Description
Mechlorethamine is a nitrogen mustard and antineoplastic agent that has been in clinical use for more than 60 years, given systemically in combination with other antineoplastic agents to treat Hodgkin disease, chronic leukemias, lung cancer and polycythemia vera. Currently, however, it is used largely as a topical gel for therapy of cutaneous T-cell lymphomas and mycosis fungoides. Given parenterally in combination with other antineoplastic agents it was associated with low rates of serum enzyme elevations during therapy, but mechlorethamine has not been implicated specifically in cases of acute, clinically apparent injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Mechlorethamine)
Mechanisms of Action: NKCC Inducer
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Canada | Colombia | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Latvia | Lithuania | Luxembourg | Norway | Poland | Portugal | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom | United States
Approved Indications: Lymphoma | Mycosis Fungoides
Known Adverse Events: Tobacco Use Disorder | Blister | Dermatitis | Dermatitis, Contact | Hyperpigmentation | Skin Ulcer | Pruritus | Inflammation | Melanoma | Skin Cancer | Oncology Unspecified | Pregnancy Outcomes
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|